

























































published: 28 July 2014
doi: 10.3389/fonc.2014.00197
X-linked inhibitor of apoptosis protein – a critical death
resistance regulator and therapeutic target for
personalized cancer therapy
Petra Obexer 1,2 and Michael J. Ausserlechner 2,3*
1 Department of Pediatrics II, Medical University Innsbruck, Innsbruck, Austria
2 Tyrolean Cancer Research Institute, Innsbruck, Austria
3 Department of Pediatrics I, Medical University Innsbruck, Innsbruck, Austria
Edited by:
Yoshihiro Suzuki-Karasaki, Nihon
University School of Medicine, Japan
Reviewed by:
Roya Khosravi-Far, Massachusetts
Institute of Technology, USA
Domagoj Vucic, Genentech, Inc., USA
*Correspondence:
Michael J. Ausserlechner ,





Defects in apoptosis regulation are one main cause of cancer development and may result
from overexpression of anti-apoptotic proteins such as inhibitor of apoptosis proteins (IAPs).
IAPs are cell death regulators that, among other functions, bind caspases, and interfere with
apoptotic signaling via death receptors or intrinsic cell death pathways. All IAPs share one
to three common structures, the so called baculovirus-IAP-repeat (BIR)-domains that allow
them to bind caspases and other proteins. X-linked inhibitor of apoptosis protein (XIAP) is
the most potent and best-defined anti-apoptotic IAP family member that directly neutralizes
caspase-9 via its BIR3 domain and the effector caspases-3 and -7 via its BIR2 domain. A nat-
ural inhibitor of XIAP is SMAC/Diablo, which is released from mitochondria in apoptotic cells
and displaces bound caspases from the BIR2/BIR3 domains of XIAP thereby reactivating
cell death execution. The central apoptosis-inhibitory function of XIAP and its overexpres-
sion in many different types of advanced cancers have led to significant efforts to identify
therapeutics that neutralize its anti-apoptotic effect. Most of these drugs are chemical
derivatives of the N-terminal part of SMAC/Diablo.These “SMAC-mimetics” either specifi-
cally induce apoptosis in cancer cells or act as drug-sensitizers. Several “SMAC-mimetics”
are currently tested by the pharmaceutical industry in Phase I and Phase II trials. In this
review, we will discuss recent advances in understanding the function of IAPs in normal
and malignant cells and focus on approaches to specifically neutralize XIAP in cancer cells.
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THE IAP FAMILY – STRUCTURE AND FUNCTION OF IAPs
Aggressive cancer cells develop due to an accumulation of genetic
and epigenetic abnormalities, defects in the intracellular signal
transduction pathways, in proliferation and migration regula-
tion, and the apoptotic cell death machinery. Cancer therapies
are mainly designed to induce programmed cell death in highly
proliferative tumor cells. When tumor cells acquire the ability to
escape drug-induced cell death, either by defects in pro-apoptotic
death regulators such as BH3-only proteins, or by overexpression
of pro-survival proteins, these events will lead to the failure of
chemotherapy. Such resistance mechanisms developed by single
cancer cells result in the selection of chemotherapy- or radiation-
resistant cancer cell subclones that finally will lead to therapy
relapse. The inhibitor of apoptosis protein (IAP) member X-linked
inhibitor of apoptosis protein (XIAP) is one culprit in the resis-
tance to various apoptotic stimuli and frequently overexpressed in
a number of different cancer types.
The mammalian IAP family consists of eight different pro-
teins that were originally described as apoptosis inhibitors as some
of them can bind and neutralize caspases. They all share the so
called baculovirus-IAP-repeat (BIR) domain and include neu-
ronal IAP (NIAP/BIRC1), cellular IAP1 (cIAP1/BIRC2), cellular
IAP2 (cIAP2/BIRC3), X-chromosome-linked IAP (XIAP/BIRC4),
Survivin/BIRC5, BIR-containing ubiquitin-conjugating enzyme
(BRUCE/Apollon/BIRC6), melanoma-IAP (ML-IAP/BIRC7), and
finally IAP-like protein 2 (ILP-2/BIRC8). XIAP, cIAP1/2, ILP-
2, and ML-IAP belong to the IAP-class 1 as they all contain a
characteristical C-terminal RING (really interesting new gene)
domain that acts as an E3-ubiquitin ligase (Figure 1). The IAPs
also exert a number of additional functions in non-apoptotic
pathways and contribute to, e.g., migration, invasion, and metas-
tasis. In this family, XIAP is the only one that inhibits cas-
pases by direct physical interaction (1). cIAP1 and cIAP2, for
example, bind caspase-3 and -7, but do not efficiently inhibit
them by physical interaction but mark them for proteasomal
degradation (2).
X-linked inhibitor of apoptosis protein contains three BIR
domains (BIR1–3) in the N-terminal half of the protein. Whereas
BIR1 interacts with proteins that modulate NFkB signaling (3),
BIR2 and BIR3 are critical for the interaction with either caspase-
3 and -7 (BIR2) or caspase-9 (BIR3), respectively. The C-terminal
part of XIAP carries a so called ubiquitin-associated (UBA)
domain for ubiquitin-binding and a RING domain with E3-
ubiquitin ligase activity, which is responsible for the recognition
of protein substrates that are ubiquitinated by XIAP. This RING
domain controls the stability of XIAP itself and also induces the

























































Obexer and Ausserlechner XIAP as a therapeutical target in cancer therapy
FIGURE 1 | Inhibitor of apoptosis protein (IAP) family. Shown is the structure of the eight mammalian IAPs with their known functional domains (description
in the main text).
proteasomal degradation of bound proteins such as caspase-3 (4)
or the mitochondrial XIAP-inhibitor SMAC/Diablo (5).
A CENTRAL FUNCTION OF XIAP IN THE REGULATION OF CELL
DEATH IN MAMMALIAN CELLS
Apoptosis is a process initiated by a large number of signals
that either activate specific membrane death receptors (extrinsic
pathway) and/or intracellular pathways controlled by members
of the Bcl2-family at the mitochondria (intrinsic pathway) (6).
Both pathways converge at the level of specific proteases, called
effector caspases that are the executioners of most forms of apop-
tosis. Fas ligand (FasL) and TRAIL, pro-apoptotic members of
the TNF family, mediate their apoptotic signal via the “extrin-
sic pathway” by binding to their cognate receptors Fas/CD95 and
TRAIL-R1 (DR4) or TRAIL-R2 (DR5), respectively. This induces
the formation of a death-inducing signaling complex (DISC) that
contains the adaptor molecule FADD and pro-caspase-8. As a con-
sequence, autocatalytic cleavage of pro-caspase-8 and activation of
a downstream caspase cascade occurs. In some cells, caspase-8 also
connects to the mitochondria through cleavage of pro-apoptotic
BID (type II cells) (7) and of the anti-apoptotic BCL2-protein
MCL1L (8), thereby providing a cross-talk between “extrinsic” and
“intrinsic” death pathways.
In this complex apoptosis signaling network mitochondria
are central executioners of programmed cell death that inte-
grate apoptotic signals, in particular in the “intrinsic pathway.”
The “intrinsic pathway” is triggered by signals such as DNA
damage, growth factor withdrawal, and anoikis. It is regulated
at the level of mitochondria by the balance of pro- and anti-
apoptotic BCL2-protein members (BCL2-rheostat). BCL2-family
proteins control apoptosis primarily through the regulation of the
mitochondrial outer membrane permeability (9, 10). Upon acti-
vation of the pro-apoptotic BCL2-proteins BAK and BAX which
form pores in the outer mitochondrial membrane, cytochrome
c and other mitochondrial proteins such as SMAC/Diablo and
Omi/Htr are released from the mitochondrial inter-membrane
space. Cytochrome c together with Apaf-1 forms the apoptosome
complex that recruits pro-caspase-9, leading to caspase-9 process-
ing and activation. The executioner caspases-3, -6, and -7 then
degrade a plethora of cellular proteins and eventually also activate
chromatin degradation via caspase-activated DNase (Figure 2).
This opens the avenue for the coordinate fragmentation of cells
into apoptotic bodies that can be recycled by neighboring cells.
As mentioned above, XIAP interferes with these final steps in
death execution as it binds partially processed initiator caspase-
9 and the executioner caspases-3 and -7 via its BIR3 and
BIR2 domains, respectively. The BIR3 domain of XIAP inter-
acts with the Apaf-1/caspase-9 holoenzyme by sequestering the
N-terminus of the small subunit of processed caspase-9. The
N-terminal tetrapeptide of the processed caspase-9 that binds
into the BIR3 pocket shares significant homology with the
N-terminus of mitochondrial SMAC/Diablo, suggesting these
two binding motives compete for XIAP–BIR3 interaction (11).
SMAC/Diablo forms homodimers and the N-terminal ends of
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FIGURE 2 | Cell death/survival pathways controlled by XIAP.
DNA-damaging chemotherapeutics induce the expression of pro-apoptotic
BCL2-proteins that antagonize the pro-survival function of BCL2, BclxL, and
MCL1. Mitochondrial cell death is initiated by pore-formation via BAK and
BAX, leading to the release of cytochrome c and other mitochondrial factors
such as SMAC/Diablo into the cytoplasm. Cytochrome c triggers apoptosome
formation and caspase-9 processing, which further activates downstream
caspases-3 and -7. Death ligands (TRAIL and FasL) either activate executioner
caspases-3 and -7 via caspase-8 directly or trigger mitochondrial cell death via
caspase-8-mediated cleavage of BID and MCL1. XIAP physically interacts with
caspase-9 at its BIR3 domain and with caspase-3 and -7 at its BIR2 domain
and thereby interferes with both death signaling pathways. In contrast, TNF
triggers a signaling cascade that, if RIP1 is ubiquitylated by cIAP1 and cIAP2,
induces NFκB activation via TAK1/TAB1 and subsequent IKKα/IKKβ/NEMO
complex activation. XIAP directly enhances this survival signal by forming a
complex with TAB1/TAK1 via its BIR1 domain (description in the main text).
SMAC/Diablo-homodimers then bind to both, the BIR2 and BIR3
domain of XIAP and displace already processed caspases from
the XIAP binding pockets. As shown in Figure 3, BIR2 and BIR3
both contain a deep, almost identical binding groove to anchor the
N-terminal alanine–valine–proline amino acids of SMAC/Diablo
(12, 13). By this process, SMAC/Diablo increases the amount of
free, activated caspase-3, -7, and -9 and promotes the final steps
of cell death execution. Another important mechanism of caspase
inhibition by XIAP involves the E3 ligase activity of the RING
domain. Schile et al. demonstrated that removal of the RING
domain in vivo stabilizes the remaining XIAP protein but surpris-
ingly also increases caspase-3 activity and TNF-sensitivity (14).
This suggests that ubiquitylation of XIAP-bound caspases repre-
sents a second important mechanism for inhibition of caspase-
mediated cell death. Thereby, high cellular levels of XIAP interfere
with “extrinsic” as well as “intrinsic” death pathways and increase
the resistance of cancer cells to various pro-apoptotic stimuli.
Similar to cIAP1, cIAP2, ML-IAP, and ILP-2, the RING domain
of XIAP is capable of conjugating different types of ubiquitin
chains to target proteins (15, 16). Protein ubiquitylation may
lead to different physiological outcome, depending on whether
one ubiquitin (monoubiquitylation) or multiple ubiquitin chains
are linked to the substrate. In principle, eight different ubiquitin
polymers can be generated. Each ubiquitin-linkage leads to differ-
ent three-dimensional structures and serves different functions as
they are differentially recognized by ubiquitin-associated (UBA)
domains. Lys48-branched ubiquitin chains label proteins for pro-
teasomal degradation, whereas Lys63 and Lys11 linear linkages
serve as docking sites in signal transduction, endocytosis and other
cellular responses such as DNA-repair [reviewed in Ref. (17)]. As
shown in Figure 1, XIAP, like cIAP1, cIAP2, and ILP-2 contains
such a UBA domain and thereby not only conjugates ubiquitin
polymers to substrates but also recognizes highly polymerized
ubiquitin chains and thereby functions as an ubiquitin receptor
(18). This implies that the functions of IAP proteins are much
more complex than simple protection against cell death by bind-
ing caspases. In the case of XIAP, the UBA domain is dispensable
for caspase inhibition but necessary for the activation of the NFκB
pathway by XIAP (18).
XIAP-INDUCED ACTIVATION OF NFκB SURVIVAL SIGNALING
The transcription factor NFκB plays a critical role in the develop-
ment and malignant progression of cancer through its strong pro-
survival functions. Due to the induction of different pro-survival
proteins, such as Bfl1/A1 (19) or XIAP (20) by NFκB and its effects
on angiogenesis, invasion, and metastasis of cancer cells, NFκB is
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FIGURE 3 | Structural basis of the interaction between SMAC/Diablo
and XIAP–BIR domains. The amino acids alanine–valine–proline at the
N-terminus of SMAC/Diablo interact with the binding groove present in the
XIAP–BIR2 and the XIAP–BIR3 domain, but also with binding pockets in the
BIR domains of a number of other IAPs. This explains why most
SMAC-mimetics designed to neutralize XIAP also target other IAPs such as
cIAP1 and cIAP2. Shown are crystal structures of the binding grooves of
XIAP–BIR2 in complex with the peptide AVPI [PDB number: 4J64 (12)] and
XIAP–BIR3 in complex with an AVPF peptide [PDB number: 2OPZ (13)].
Surfaces of binding pockets were calculated using LigandScout (Inte:ligand
GmbH, Vienna). Color encoding represents aggregated
lipophilicity/hydrophobicity (hydrophobic areas in yellow).
one important culprit for the development of malignant diseases.
This induction of resistance genes is in particular important in the
case of radio-resistance, as ionizing irradiation also activates NFκB
thereby contributing to both, DNA damage-induced apoptosis but
also to a strong pro-survival signal in irradiated cells. DNA-double
strand breaks induced by irradiation activate ATM, which in turn
leads to the formation of a complex of p53-inducible death domain
(PIDD)/RIP1 and NEMO (21) causing sumoylation and ubiqui-
tylation of NEMO. This further activates the IKKα/IKKβ/NEMO
signaling platform. This complex then phosphorylates IκBα, caus-
ing Lys48 ubiquitylation of IκBα and thereby, relieves NFκB from
inhibition. It is believed that this strong NFκB-driven pro-survival
signal during DNA-double strand breaks provides time to repair
genotoxic stress-induced DNA damage.
One important upstream inducer of the NFκB pathway is the
tumor necrosis factor alpha (TNFα)/TRADD/TRAF2 signaling
complex (22) that is critically regulated by cIAPs (23, 24). TRAF2
directly interacts with cIAP1 (25, 26) and cIAP2 (27, 28) via the
BIR1 domain, which leads to Lys11/Lys63 linear ubiquitylation of
RIP1 (29–31) thereby generating a platform for the recruitment of
TGFβ-activated kinase 1 (TAK1)/TAK1 binding protein 1 (TAB1),
which promotes activation of the IKKα/IKKβ/NEMO signaling
complex and thereby NFκB (32). Since TNFα is a transcriptional
target of NFκB this signaling cascade constitutes an autoregulatory
feed-back loop. In the absence of cIAP1/2 RIP1 is not ubiquity-
lated (24), which induces its interaction with the FADD/Caspase-8
complex and triggers apoptotic cell death (33).
The TAB1/TAK1 complex represents an important crosslink
between NFκB signaling and XIAP: while the BIR2 and BIR3
domains of XIAP bind caspases, SMAC/Diablo or other substrates,
the BIR1 domain directly interacts with the N-terminal domain
of TAB1. Originally, it was thought that TAB1 is some kind of
pseudophosphatase that regulates the accessibility of phosphory-
lated amino acids on TAK1 or downstream substrates and thereby
modulates NFκB signaling via TAK1 (34). However, Lu et al. clearly
demonstrated by crystallizing the TAB1/XIAP–BIR1 complex that
the XIAP–BIR1 domain, for which no other function has been
described until now, directly binds one molecule of TAB1 and
thereby causes the formation of a complex where a dimer of XIAP-
molecules binds two TAB1 proteins, which in turn recruit TAK1
proteins (3). This dimerization is important for TAK1 activation,
as mutation of the BIR1 dimerization interface reduces the abil-
ity to activate NFκB. SMAC/Diablo does not directly interact with
the BIR1 domain of XIAP, but interferes with XIAP–TAB1 interac-
tion most likely by steric exclusion (3) and thereby impairs NFκB
signaling via XIAP.
XIAP OVEREXPRESSION IN CANCER
X-linked inhibitor of apoptosis protein is aberrantly expressed in a
variety of human cancers and mediates resistance to chemothera-
peutic drugs in specific subgroups of patients. High XIAP expres-
sion results in lack of therapy response leading to a change of
therapy regimen and combined treatment with high dose radio-
therapy. In cell lines isolated from acute myeloid leukemia (AML)
XIAP overexpression is frequently observed: Tamm et al. investi-
gated the expression of IAPs in 60 human cancer cell lines at mRNA
and protein levels and found XIAP expressed in most malignant
cells analyzed. The XIAP protein level correlated with the sen-
sitivity to the anti-cancer drug cytarabine and other nucleosides
(35). In childhood de novo AML XIAP overexpression is asso-
ciated with an unfavorable response to induction chemotherapy
and with a worse 3 year relapse free survival rate (36). Further-
more, XIAP shows maturation dependent expression differences
and is associated with intermediate/poor cytogenetics in this child-
hood malignancy (37). In adult de novo AML aberrantly expressed
XIAP is associated with monocytic differentiation in normal and
malignant myelopoiesis, and also with the overall survival (38). In
childhood acute lymphoblastic leukemia (ALL) the XIAP expres-
sion is highly increased by post-transcriptional regulation and is
associated with poor in vivo glucocorticoid response and outcome.
Resistance to glucocorticoid-induced apoptosis is one of the major
risk factors for relapse and poor outcome in ALL (39). For child-
hood neuroblastoma, no clear clinical data is available about XIAP
expression and clinical outcome, although XIAP-inhibitors signif-
icantly affect tumor growth and death resistance of neuroblastoma
in vitro and in vivo (40, 41).
Furthermore increased XIAP levels have also been reported for
ovarian carcinoma (42), B-cell Non-Hodgkin and Hodgkin lym-
phoma (43), clear cell renal cancer (44, 45), esophageal carcinoma
(46), and non-small cell lung cancer (47). Chemoresistance after
cisplatin treatment is linked to enhanced expression of XIAP in
ovarian carcinoma cells (42). In clear cell renal cancer, the XIAP
expression is an independent prognostic marker as it correlates
with tumor aggressiveness. During clear cell renal cancer progres-
sion, an increase of XIAP relative to SMAC/Diablo occurs, which
may contribute to apoptosis resistance (44, 45). Patients with renal
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cell carcinoma with low XIAP expression had a longer postop-
erative disease-specific survival as compared to those with high
expression in the 5 year follow-up (48). Treatment of XIAP siRNA
in combination with paclitaxel, cisplatin, fluorouracil, and etopo-
side enhanced chemosensitivity in esophageal carcinoma cell lines
demonstrating that knockdown of XIAP may be a strategy for
cancer therapy in patients with esophageal carcinoma (46). Also
in non-small cell lung cancer, the high expression level of XIAP is
involved in the pathogenesis of this cancer (47). In human prostate
(49, 50) and hepatocellular carcinoma cells, the XIAP expression
correlates with apoptosis resistance and increased metastatic foci
in vivo (51). Patients with XIAP-positive hepatocellular carcinoma
tumors showed a higher risk of relapse – in this tumor type XIAP
can be defined as a biomarker that promotes metastasis and tumor
recurrence (51).
The main challenge in the use of XIAP as a biomarker and
therapeutic target is that, although XIAP is found overexpressed
in many cancer tissues, its expression is not always correlated with
adverse clinical outcome. This questions the relevance of XIAP
as the critical culprit for therapy resistance in those malignan-
cies, where elevated expression is observed. For example, although
specifically elevated in non-small cell lung cancer (47), a recent
study suggested no significant correlation between XIAP expres-
sion and patient outcome (52). In prostate cancer, XIAP is sig-
nificantly higher expressed in the cancer tissue than in prostatic
intraepithelial neoplasia, or in normal or benign hyperplasia,
but, surprisingly, high expression of XIAP predicts lower risk
of tumor recurrence than low or intermediate XIAP expression
in the tumor tissue (53). This means that XIAP may play dis-
tinct roles in different types/subtypes of cancer and although it
may serve as a biomarker for cancer tissue, targeting of XIAP
in specific patient subgroups has to be carefully evaluated. In
this respect, Xu and colleagues recently reported that significantly
higher levels of XIAP are detected in breast cancer tissue versus
normal breast tissue, but they could not confirm a correlation
between XIAP expression, disease-free survival, and overall sur-
vival of breast cancer patients. However, when analyzing patient
subgroups, they discovered that basal-like breast cancer patients
with elevated XIAP expression had a significantly increased risk
of tumor recurrence, suggesting that XIAP is predictive for poor
relapse free survival in this patient subgroup (54). This suggests
that additional clinical studies are required to identify those can-
cer patient subgroups that benefit from XIAP-targeted therapy.
Therefore,XIAP in combination with other biomarkers may evolve
as a predictive tool and as a drug target in personalized cancer
therapy.
STRATEGIES TO INTERFERE WITH ABERRANTLY EXPRESSED
XIAP IN CANCER CELLS
Patients that belong to subgroups where high cancer cell spe-
cific XIAP expression causes poor cancer therapy response may
have a therapeutic benefit if they are treated with XIAP-targeting
drugs that specifically neutralize the protective effect of XIAP. Such
oncogene-specific neutralization might reduce the required doses
of chemotherapeutics and thereby also lower therapy-related side
effects. Therefore, XIAP is thought to be an excellent drug target
for personalized cancer therapy.
In a classical approach by using antisense oligonucleotides
(55), siRNA (56, 57) or morpholino-antisense (58), the decrease
of the mRNA and protein levels of XIAP was shown to sensi-
tize drug-resistant cancer cells to therapy-induced apoptosis or
to induce even spontaneous cell death specifically in cancer cells.
This is especially true for cancer cells with defective mitochon-
drial death signaling: repression of XIAP mRNA by RNAi or the
specific XIAP-transcription-inhibitory compound Mithramycin A
(59) overcomes TRAIL-resistance in carcinoma cells that show
deregulation of the intrinsic apoptosis signaling pathway (60).
One such antisense strategy using the mixed backbone anti-
sense oligonucleotides AEG35156 (Aegera Therapeutics) entered
clinical trials, although several Phase I studies were terminated, one
due to severe neurotoxicity (61). In a Phase I/II trial AEG35156 was
effective in repressing XIAP mRNA levels and inducing apoptosis
in CD34+CD38− AML stem cells. All Phase II patients showing
AML stem cell apoptosis also achieved response (62). However, an
open-label randomized Phase II trial of reinduction chemotherapy
using a combination of high dose cytarabine and idarubicine ther-
apy with and without the antisense oligonucleotides AEG35156
showed no improvement in the remission rates in patients with
primary refractory AML although the therapy was well tolerated
by the involved patients (63). As a consequence of these results,
clinical studies on AEG35156 have been discontinued.
A second and even more promising approach is to sensitize
cancer cells to chemotherapeutic drugs by functionally blocking
XIAP via chemical compounds that bind into the BIR3 domains.
The fact that SMAC/Diablo acts as a natural XIAP-antagonist and
that the N-terminal ends of SMAC/Diablo bind with high affinity
to the same binding pockets on the BIR2 and the BIR3 domain as
caspases has led to the development of so called“SMAC-mimetics”
that occupy the SMAC/Diablo-binding pockets in BIR domains of
IAPs (Figure 3). These SMAC-mimetics are compounds struc-
turally derived from the processed N-terminus of SMAC/Diablo
and are in principle chemical derivatives of the peptide sequence
AVPI (N-terminal part of SMAC/Diablo with the mitochondrial
transit-sequence cleaved off). A plethora of different high affin-
ity compounds have been developed to break the apoptosis block
imposed by XIAP and other IAPs. However, some drawbacks also
emerged with the development of these compounds that result
from the complex cellular functions of their targets and from
the fact that similar to the SMAC/Diablo protein almost all of
these compounds target also the BIR domains of other IAPs, most
prominently of cIAP1 and cIAP2, which leads to unwanted and
in part toxic side effects. Whereas the genetic deletion of XIAP
causes only a very mild phenotype in knock-out mice (64, 65),
targeting of multiple IAPs, as it is achieved by high affinity SMAC-
mimetics, may be detrimental to an organism as demonstrated by
the deletion of cIAP1 together with cIAP2 or XIAP (66).
An important discovery for the understanding of SMAC-
mimetic side effects, especially in combination therapies, was the
observation that XIAP discriminates between type I and type II
cells for Fas-induced apoptosis: in type I cells death receptor-
induced activation of caspase-8 is sufficient to activate executioner
caspases and thereby to induce apoptotic cell death independent
of Bax and Bak. In type II cells, however, for full caspase-3 acti-
vation an amplification loop via mitochondria is needed. In these
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cells, mitochondrial outer membrane permeabilization is triggered
by truncation of the BH3-only protein BID, which counteracts
pro-survival proteins such as Bcl2 or BclxL, leads to Bax and
Bak oligomerization, cytochrome c release, and caspase-9 acti-
vation at the apoptosome complex. Although type I cells (e.g.,
thymocytes) and type II cells (e.g., hepatocytes, pancreatic beta
cells) contain similar steady state levels of XIAP, upon Fas bind-
ing to its cognate receptor, XIAP levels in type I cells are reduced,
whereas XIAP concentration in type II cells increases. When XIAP
is repressed or neutralized either by genetic ablation or by the
use of the SMAC-mimetic BV6 (67) type II cells become sensitive
to death receptor-induced cell death (68). This suggests that the
activation of caspases in hepatocytes is normally blocked by XIAP
and neutralization of XIAP may lead to significant damage of liver
cells. In line with this study, Varfolomeev and colleagues found
that BV6 in combination with FasL or DR5 agonistic antibodies
rescues the effect of BID knockdown for apoptosis induction in
different cancer cells (69).
Another important aspect of cell death regulation by IAP antag-
onists involves TNF-signaling and the discrimination between
death induction via caspase-8 or survival signaling via stimulation
of NF-κB signaling as outlined in Figure 2. In 2007, three indepen-
dent papers reported different SMAC-mimetics, which induced
caspase-8-dependent cell death when used as single agents (67, 70,
71). NF-κB stimulates the production of TNFα and activates the
TNFα/TRADD/TRAF2 complex that associates with cIAP1 and
cIAP2. cIAP1/2 ubiquitylate RIP1 (29–31) that in turn activates
the NFκB pathway. SMAC-mimetic-induced inhibition of cIAP1
and cIAP2 results in auto-ubiquitination and proteasomal degra-
dation of cIAP1/2 within minutes (67, 71), which further prevents
ubiquitination of RIP1. As a consequence, RIP1 associates with
the FADD/caspase-8 complex and triggers caspase-8-dependent
cell death (33).
Due to these pleiotropic effects of SMAC-mimetics several
drugs were designed that exert an improved activity against either
XIAP or cIAP1/cIAP2. Ndubaku et al. described the structure-
based design of SMAC-mimetics (compound C1–C3) that demon-
strate high affinity to the BIR3 region of cIAP1 and cIAP2 (CS3:
Ki cIAP1: 16 nM; Ki cIAP2: 85 nM) but only moderate affinity in
micromolar range to the BIR3 domain of XIAP (Ki: >34µM).
Although, these compounds stimulated the NFκB pathway and
induced cell death, these cIAP-selective compounds were signifi-
cantly less effective than pan-SMAC-mimetics suggesting that for
efficient cell death induction neutralization of XIAP and cIAP1/2
are required (72). To identify XIAP-specific SMAC-mimetics,
XIAP-BIR2 domain specific small compounds have been designed
that bind with low micromolar affinity to the XIAP-BIR2 domain
and show significantly reduced Ki values for the BIR3 domain
(73, 74). However, these authors did not provide data on the
affinity to cIAP1/2. A recent report bei Kester et al. described
the optimization of benzodiazepinones with high affinity (IC50
45 nM) and high selectivity for the XIAP-BIR2 domain. These
authors also provided evidence that the affinity of this compound
to the cIAP1–BIR2 domain was about 500-fold less than to the
XIAP–BIR2 domain (75). Although these are experimental drugs
they are valuable tools to dissect the effects of targeting different
domains on IAPs by small compounds in cancer cells.
FIGURE 4 | Example for a SMAC-mimetic bound to the XIAP–BIR3
binding pocket. Compound 21, a chemical derivative structurally related to
the AVPI peptide was crystallized in complex with a XIAP–BIR3 protein
fragment [PDB number: 2JK7 (79)]. From the calculation of the binding
pockets, the similarity in the mode of binding between this SMAC-mimetic
and the AVPF peptide (Figure 3) becomes evident. The surface of the
binding pocket was calculated using LigandScout (Inte:ligand GmbH,
Vienna). Color encoding shows hydrophobic areas in yellow.
A number of different SMAC-mimetics have demonstrated
good anti-cancer activity in preclinical studies. On one hand,
there are the monovalent SMAC-mimetics, small chemical com-
pounds that occupy the BIR domains of XIAP and other IAPs
and are able to sensitize cells to apoptotic stimuli or to induce
apoptosis [reviewed in Ref. (76)]. Among the first compounds
that bind as monomers to the BIR3 domains of IAPs were the
synthetic mimetic SM-12d (77) and the natural compound embe-
lin (78), both identified by the same group at the University of
Michigan. The mode of binding of the mimetic compound 21 was
solved by the same group [PDB number 2JK7 (79)] also shown
in Figure 4 with the surface of the binding pocket calculated
using LigandScout software. The striking similarity between the
AVPF peptide (Figure 3) and compound 21 in the mode of binding
to XIAP–BIR3 becomes evident when comparing binding pock-
ets calculated on the basis of crystal structures. The orally active
compound AT-406 (Ascenta Therapeutics), a further optimized
chemical derivative of compound 21 has reached clinical trials in
the meantime (80).
Other compounds, e.g., small molecular XIAP-inhibitors from
IDUN Pharmaceuticals/Pfizer were shown to cooperate with
TRAIL to induce apoptosis and to inhibit clonogenic sur-
vival of childhood acute leukemia cells. These inhibitors kill
leukemic blasts ex vivo. In vivo, they reduce leukemic burden
in a mouse model of pediatric ALL engrafted in non-obese dia-
betic/severe combined immunodeficient mice (81). The authors
also demonstrated that these inhibitors act synergistically with
agonistic anti-CD95 antibodies or MegaFASL to induce apopto-
sis and reduce clonogenic survival in childhood acute leukemia
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cells (82). Additional early small-molecule XIAP-inhibitors such
as the polyphenylurea-based antagonists 1396-12 and 1396-34
efficiently inhibited the growth of prostate cancer xenografts in
mice and showed little toxicity on normal tissues (83). These
polyphenylurea-based antagonists also exerted an antimetastatic
activity against circulating metastatic prostate cancer cells (49).
However, only few of these compounds demonstrated sufficient
affinity and specificity to be further developed into clinical studies.
LCL-161, an orally active, monovalent SMAC-mimetic developed
by Novartis also reached clinical studies and completed a Phase I
multicenter trial for the treatment of solid tumors. Similar to LCL-
161, the monovalent compound GDC-0152 developed by Genen-
tech (84) has successfully completed a Phase I trial in patients with
locally advanced or metastatic solid tumors (ClinicalTrials.gov).
A second class of SMAC-mimetics, the so called biva-
lent/dimeric mimetics consist in principle of two BIR-binding
monovalent units and a bridging chemical linker. These dimeric
compounds generally display a significantly higher affinity for
IAPs than the monovalent mimetics and they are more effective
in triggering apoptosis. Bivalent SMAC-mimetics such as SM-
164 (85) simultaneously bind two BIR domains and despite their
size also efficiently enter cells and are more potent than high
affinity monovalent SMAC-mimetics in cell culture and animal
experiments. Their disadvantage is that in contrast to monovalent
XIAP-antagonists like LCL-161 or AT-406, which can be orally
applied, these larger compounds require intravenous administra-
tion. Two of these compounds TL32711/Birinipant (Tetralogic
Pharamceuticals) (86) and HGS1029 (Human Genome Sci-
ences) also successfully completed Phase I trials on advanced
ovarian, peritoneal cancer, other refractory solid tumors and
lymphoma (TL32711), and advanced solid tumors (HGS1029)
allowing the determination of the maximum tolerable dose
(MTD).
Phase I studies assess the safety and tolerability of drugs to
determine the MTD for further clinical trials. The fact that four
SMAC-mimetics already passed this primary phase suggests that
these compounds are tolerated. However, SMAC-mimetics are
expected to act mainly also as chemosensitizing drugs and to
this end all combination Phase I trials, e.g., AT-406 in combina-
tion with daunorubicine/cytarabine or TL32711 in combination
with gemcitabine were terminated. Nonetheless, for all SMAC-
mimetics that passed Phase I trials currently the recruitment for
combination therapy Phase I trials has been launched. Phase II
clinical trials testing the efficacy of the XIAP-antagonists have been
set up in the case of LCL-161 for the treatment of triple negative
breast cancer and forms of myelofibrosis as well as for TL32711 for
the treatment of patients with acute myelogenous leukemia and
ALL (ClinicalTrials.gov).
CONCLUSION AND PERSPECTIVES
Primary or acquired resistance of cancer to conventional chemo-
and radiotherapy is the main cause for cancer-related death and
remains a significant challenge in the therapy of malignant dis-
eases. IAPs represent possible targets for specifically neutralizing
therapy resistance mechanisms that lead to therapy failure and
relapse. XIAP on one hand inhibits cell death execution by physical
interaction with caspases and by causing their proteasomal degra-
dation, on the other hand it also triggers survival signaling via the
NFκB pathway thereby directly shifting the survival/death balance
in cancer cells toward death resistance and NFκB-driven survival.
The results from a plethora of preclinical studies, which demon-
strate that XIAP-antagonists prove efficacy in enhancing drug- and
radiotherapy-related cancer cell death and in specific cancer types
even cause tumor remission are very promising. Therefore, in com-
bination with diagnostic methods to identify patient subgroups
that benefit from these novel compounds, XIAP-antagonists may
be developed into highly efficient drugs in personalized medicine
to overcome therapy resistance in cancer treatment. As several
SMAC-mimetics have also been shown to neutralize circulating
cancer cells, such drugs may also be useful in the clinics to prevent
local recurrence of tumors after treatment as well as metastasis.
Therefore, the targeting of IAPs in conventional cancer therapy
has the potency to significantly improve success rates of cancer
treatment and the survival of patients.
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